Colchicine in the treatment of cutaneous leukocytoclastic vasculitis. Results of a prospective, randomized controlled trial.

Colchicine in the treatment of cutaneous leukocytoclastic vasculitis. Results of a prospective, randomized controlled trial. Research Abstract Details 

Research Abstract Table of Contents

Jump to the:

Colchicine in the treatment of cutaneous leukocytoclastic vasculitis. Results of a prospective, randomized controlled trial. Abstract Text:

BACKGROUND AND DESIGN: Cutaneous leukocytoclastic vasculitis is an inflammatory vascular disease with a variable course. There is no defined therapy for this entity. Contradictory data on the effect of colchicine have been reported. To determine the efficacy of colchicine in cutaneous leukocytoclastic vasculitis, 41 patients were randomly selected to receive oral colchicine, 0.5 mg twice daily, or topical emollients. Response to treatment was judged according to the reduction in the number of lesions. After 1 month, in those patients in whom a complete or no response was achieved, therapy was withdrawn; in those with a partial response, treatment was maintained for the following 2 months. At the end of 3 months, treatment was continued only in those patients in whom a relapse occurred. RESULTS: Twenty patients in each group completed 1 month of treatment. One patient taking colchicine dropped out because of diarrhea. At the end of the first month of the study, five patients in the control group and four in the colchicine group achieved a complete response. Nine patients who had a partial response (four in the colchicine group and five in the control group) continued to receive treatment for the following 2 months. Three patients in the colchicine group suffered a relapse after discontinuing therapy but experienced remission with reinstitution of therapy. At the end of the 3 month period, 12 patients in the colchicine group and 10 patients in the control group showed no significant response. Complete response was achieved in five patients in the colchicine group and in seven in the control group. At the 1-year follow-up, 10 patients in each group had no clinical evidence of cutaneous vasculitis. CONCLUSIONS: Colchicine had no significant therapeutic effect in this controlled study. However, the finding that relapse occurred on cessation of colchicine therapy in three complete responders suggests that colchicine can be effective in some patients, despite our negative results.

Colchicine in the treatment of cutaneous leukocytoclastic vasculitis. Results of a prospective, randomized controlled trial. Publishing Authors By Initials

For similar cardiovascular diseases: vascular diseases: vasculitis: vasculitis, hypersensitivity research abstracts see: cardiovascular diseases: vascular diseases: vasculitis: vasculitis, hypersensitivity research

PUBMED ID PMID:

MEDLINE DATE:

Colchicine in the treatment of cutaneous leukocytoclastic vasculitis. Results of a prospective, randomized controlled trial. Journal Published:

PUBLICATION TYPE: Research Support, Non-U.S. Gov

Journal: Archives of dermatology

VOLUME: 131

Page Numbers: 1399-402

Journal Abbreviation: Arch Dermatol

ISSN: 0003-987X

DAY: 17

MONTH: Dec

YEAR: 1995

Colchicine in the treatment of cutaneous leukocytoclastic vasculitis. Results of a prospective, randomized controlled trial. Information

Number of References:

LANGUAGE: eng

NlmUniqueID: 372433

Colchicine in the treatment of cutaneous leukocytoclastic vasculitis. Results of a prospective, randomized controlled trial. Keywords Mesh Terms:

KEYWORDS: Vasculitis, Hypersensitivity

MESH TERMS: pathology

Chemical & Substance for Abstract: Colchicine in the treatment of cutaneous leukocytoclastic vasculitis. Results of a prospective, randomized controlled trial. Information

Substance Name: Colchicine

Registry Number: 64-86-8

Grant and Affiliation Information for Colchicine in the treatment of cutaneous leukocytoclastic vasculitis. Results of a prospective, randomized controlled trial.

AFFILIATION: Department of Dermatology, Ciutat Sanitària i Universitària de Bellvitge, Universitat de Barcelona, Spain.

Country: UNITED STATES

AGENCY:

GRANT:

ACRONYM:

MEDLINETA: Arch Dermatol

REFSOURCE:

DATABASENAME:

ACCESSION NUMBER:

Number Hits: 0

Colchicine in the treatment of cutaneous leukocytoclastic vasculitis Results of a prospective, randomized controlled trial Related Publications

• Adhesion molecule expression and endothelial cell activation in cutaneous leukocytoclastic vasculitis. An immunohistologic and clinical study in 42 patients.
• Antineutrophil cytoplasmic antibodies in leukocytoclastic vasculitis.
• Colchicine in the treatment of cutaneous leukocytoclastic vasculitis. Results of a prospective, randomized controlled trial.
• Foreign bodies in granulomatous cutaneous lesions of patients with systemic sarcoidosis.
• Palmoplantar keratoderma secondary to chronic acral erythema due to tegafur.
• Subcutaneous sarcoidosis.
• Traumatic panniculitis.